title: Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry.
abstract: Remarkable methodological advances in the past decade have expanded the application of liquid chromatography coupled with mass spectrometry (LC/MS) analysis of biotherapeutics. Currently, LC/MS represents a promising alternative or supplement to the traditional ligand binding assay (LBA) in the pharmacokinetic, pharmacodynamic, and toxicokinetic studies of protein drugs, owing to the rapid and cost-effective method development, high specificity and reproducibility, low sample consumption, the capacity of analyzing multiple targets in one analysis, and the fact that a validated method can be readily adapted across various matrices and species. While promising, technical challenges associated with sensitivity, sample preparation, method development, and quantitative accuracy need to be addressed to enable full utilization of LC/MS. This article introduces the rationale and technical challenges of LC/MS techniques in biotherapeutics analysis and summarizes recently developed strategies to alleviate these challenges. Applications of LC/MS techniques on quantification and characterization of antibody biotherapeutics are also discussed. We speculate that despite the highly attractive features of LC/MS, it will not fully replace traditional assays such as LBA in the foreseeable future; instead, the forthcoming trend is likely the conjunction of biochemical techniques with versatile LC/MS approaches to achieve accurate, sensitive, and unbiased characterization of biotherapeutics in highly complex pharmaceutical/biologic matrices. Such combinations will constitute powerful tools to tackle the challenges posed by the rapidly growing needs for biotherapeutics development.
authors.affiliation: Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York (B.A., M.Z., J.Q.); New York State Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York (B.A., M.Z., J.Q.).
authors.forename: Bo
authors.initials: B
authors.lastname: An
authors.affiliation: Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York (B.A., M.Z., J.Q.); New York State Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York (B.A., M.Z., J.Q.).
authors.forename: Ming
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York (B.A., M.Z., J.Q.); New York State Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York (B.A., M.Z., J.Q.) junqu@buffalo.edu.
authors.forename: Jun
authors.initials: J
authors.lastname: Qu
mesh_terms: D000906:Antibodies / Q000032:analysis* / Q000627:therapeutic use; D002853:Chromatography, Liquid; D006801:Humans; D008024:Ligands; D057230:Limit of Detection; D013058:Mass Spectrometry / Q000379:methods*; D010599:Pharmacokinetics
chemical_list: D000906:Antibodies; D008024:Ligands